AKT1 and Peritoneal Fibrosis: In this study, we established a rat model of PF and a high glucose-induced PF cell model, and verified in vivo and in vitro that PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin exert anti-peritoneal fibrosis effects through the PI3K/AKT/mTOR pathway during the process of fibrosis promoted by HG conditions.